Efficacy and tolerability of terbinafine 1% emulsion gel in patients with tinea pedis

Hollmen, KA; Kinnunen, Tuomo; Kiistala, U; Väänänen, Antti; I, Saarelainen; Cuyper, Christa De; Decroix, J; Broeckx, Walter; Karvonen, Jaakko

doi:10.1046/j.1468-3083.2002.368_6.x

Cited by 11 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Response rates are signifi cantly greater than observed with the vehicle alone wherein mycologic cure and overall effi cacy range from 22% to 37% and 4% to 26%, respectively. 83,[93][94][95][96] Mycological cure rates, after 1 week of treatment, are also comparable to or greater than those observed after 4 weeks of treatment with topical azole preparations. [97][98][99] Despite the advantage of a strong effi cacy profi le with the application of terbinafi ne for one week, efforts to simplify topical administration, decrease treatment duration and improve compliance has lead to the development of a polymeric fi lm-forming solution (FFS) designed as a "one-time" dose.…”

Section: Cutaneous Dermatophytosesmentioning

confidence: 84%

Update on terbinafine with a focus on dermatophytoses

Newland¹,

Abdel‐Rahman

2009

CCID

View full text Add to dashboard Cite

Since terbinafi ne was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superfi cial fungal infections, aided by unique pharmacologic and microbiologic profi les. This article reviews mode of action, antimycotic spectrum and disposition profi le of terbinafi ne. It examines the data, accumulated over 15 years, on the comparative effi cacy of terbinafi ne (vs griseofulvin, itraconazole, fl uconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.

show abstract

Section: Cutaneous Dermatophytosesmentioning

confidence: 84%

Update on terbinafine with a focus on dermatophytoses

Newland¹,

Abdel‐Rahman

2009

CCID

View full text Add to dashboard Cite

show abstract

“…Early studies indicated that twice‐daily treatment with 1% terbinafine for 1 week was as effective as twice‐daily administration of clotrimazole 1% for 4 weeks 83,84 . Recent studies have demonstrated that terbinafine 1% is effective with once‐daily treatment 85–87 . A recently developed terbinafine 1% emulsion gel formulation has been shown to be significantly more effective than placebo when applied once daily for 7 days in a study of 101 patients with tinea pedis 86 .…”

Section: Do Approaches Employed To Improve Adherence To Oral Therapy mentioning

confidence: 99%

Adherence to topical dermatological therapy: lessons from oral drug treatment

Gupta

Mallefet

Kress

et al. 2009

British Journal of Dermatology

View full text Add to dashboard Cite

Patients are remarkably nonadherent to medical treatment regimens across all diseases and classes of therapy, and it has been estimated that nonadherence to drug treatment is responsible for as many as 10% of all hospital admissions. Nonadherence to treatment also has significant negative effects on treatment outcomes across a wide range of diseases. Patient-related factors such as age, ethnicity, literacy (including health literacy), health beliefs, and socioeconomic conditions have been shown to influence adherence to oral therapy. Medication-related factors, such as regimen complexity and duration of treatment, also impact on adherence. Variables that significantly influence adherence to oral drugs have similar effects on adherence to topical therapy. Both educational and psychological interventions along with simplification of dosing regimens can significantly improve adherence to oral therapy and limited evidence indicates that these approaches are also effective in patients receiving topical therapy. There is very little information about the effects of dosing regimens on adherence to topical medical therapy. The advent of new drug formulations that permit once-daily or single-dose drug application will, however, permit evaluation of different topical treatment regimens on adherence and treatment outcomes in patients with dermatological disease.

show abstract

“…Für die Indikation Tinea pedis dienten im Einzelnen Clotrimazol [14,15,16,17,18,19,20,21,22,23,24,25,26,27], Miconazol [28,29], Bifonazol [30,31], Butenafin [32] und Naftifin [33] …”

Section: Vergleichsstudien Terbinafin Vs Andere Antimykotikaunclassified

Terbinafin-Topika

Schmid‐Wendtner

Körting

2008

Hautarzt

View full text Add to dashboard Cite

Superficial fungal infections are common and worldwide in distribution. Latest estimates suggest one- third of the population in Europe has a fungal infection of their feet, with dermatophyte infections of the skin of the feet (tinea pedis) most common. Tinea pedis interdigitalis is by far most common and can be effectively treated topically. Common agents include azoles, hydroxypyridones and allylamines, with morpholines used less frequently. While most antifungals have mainly fungistatic effects on dermatophytes, the causative agents of tinea pedis, terbinafine--an allylamine--is fungicidal. Due to this feature shorter treatment periods are possible using topical terbinafine. For effective treatment of uncomplicated tinea pedis interdigitalis, azole cream preparations are often used twice daily for four weeks whereas 1% terbinafine cream can be applied once a day for one week. Since 2006, 1% terbinafine is also available as a film-forming solution (FFS), which makes single-dose treatment possible. FFS may prove superior in daily practice with increased compliance and thus reduced recurrences.

show abstract

Efficacy and tolerability of terbinafine 1% emulsion gel in patients with tinea pedis

Cited by 11 publications

References 6 publications

Update on terbinafine with a focus on dermatophytoses

Update on terbinafine with a focus on dermatophytoses

Adherence to topical dermatological therapy: lessons from oral drug treatment

Terbinafin-Topika

Contact Info

Product

Resources

About